Rep. Julie Johnson Sells Off Shares of Quest Diagnostics Incorporated (NYSE:DGX)

Representative Julie Johnson (D-Texas) recently sold shares of Quest Diagnostics Incorporated (NYSE:DGX). In a filing disclosed on December 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Quest Diagnostics stock on November 3rd. The trade occurred in the Representative’s “MERRILL LYNCH LONG TERM GROWTH” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Cigna Group (NYSE:CI) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Xcel Energy (NASDAQ:XEL) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Capital One Financial (NYSE:COF) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Wells Fargo & Company (NYSE:WFC) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 11/13/2025.

Quest Diagnostics Stock Up 0.1%

NYSE DGX traded up $0.16 during trading on Friday, hitting $176.31. 437,610 shares of the company traded hands, compared to its average volume of 1,105,189. The company has a market capitalization of $19.61 billion, a P/E ratio of 20.68, a PEG ratio of 2.41 and a beta of 0.62. The business has a fifty day simple moving average of $183.51 and a 200 day simple moving average of $179.80. Quest Diagnostics Incorporated has a 12 month low of $148.70 and a 12 month high of $197.55. The company has a current ratio of 1.13, a quick ratio of 1.04 and a debt-to-equity ratio of 0.71.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Tuesday, October 21st. The medical research company reported $2.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.51 by $0.09. Quest Diagnostics had a return on equity of 15.47% and a net margin of 8.91%.The firm had revenue of $2.82 billion during the quarter, compared to analysts’ expectations of $2.73 billion. During the same quarter in the prior year, the business earned $2.30 earnings per share. The company’s revenue was up 13.2% on a year-over-year basis. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS. As a group, sell-side analysts predict that Quest Diagnostics Incorporated will post 9.7 EPS for the current year.

Quest Diagnostics Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 28th. Stockholders of record on Tuesday, January 13th will be paid a dividend of $0.80 per share. The ex-dividend date of this dividend is Tuesday, January 13th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.8%. Quest Diagnostics’s dividend payout ratio (DPR) is 37.56%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Piper Sandler lifted their target price on shares of Quest Diagnostics from $190.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, October 27th. Morgan Stanley set a $207.00 price objective on Quest Diagnostics and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Leerink Partners increased their target price on Quest Diagnostics from $203.00 to $210.00 and gave the company an “outperform” rating in a research note on Tuesday, October 21st. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Quest Diagnostics in a research report on Wednesday, October 8th. Finally, Baird R W lowered Quest Diagnostics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 25th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $197.27.

Insider Transactions at Quest Diagnostics

In other news, SVP Michael E. Prevoznik sold 28,288 shares of Quest Diagnostics stock in a transaction on Tuesday, September 23rd. The stock was sold at an average price of $187.12, for a total value of $5,293,250.56. Following the transaction, the senior vice president owned 38,117 shares in the company, valued at approximately $7,132,453.04. This trade represents a 42.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Vicky B. Gregg sold 1,250 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $191.76, for a total transaction of $239,700.00. Following the transaction, the director owned 17,037 shares of the company’s stock, valued at approximately $3,267,015.12. This represents a 6.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 94,461 shares of company stock worth $17,957,361. Corporate insiders own 8.16% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of Quest Diagnostics by 2.1% in the second quarter. Vanguard Group Inc. now owns 14,233,576 shares of the medical research company’s stock valued at $2,556,777,000 after acquiring an additional 296,860 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Quest Diagnostics by 9.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,984,238 shares of the medical research company’s stock valued at $1,012,534,000 after purchasing an additional 493,960 shares during the period. State Street Corp grew its holdings in Quest Diagnostics by 0.8% in the 3rd quarter. State Street Corp now owns 5,223,930 shares of the medical research company’s stock valued at $995,577,000 after buying an additional 38,931 shares in the last quarter. Boston Partners lifted its holdings in shares of Quest Diagnostics by 32.8% during the third quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock worth $767,978,000 after buying an additional 997,033 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Quest Diagnostics by 7.5% in the 2nd quarter. Geode Capital Management LLC now owns 2,982,415 shares of the medical research company’s stock worth $533,563,000 after purchasing an additional 208,261 shares in the last quarter. Institutional investors and hedge funds own 88.06% of the company’s stock.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.